Clinical Trials Browser

Phase 2 × Carcinoma, Hepatocellular × futibatinib × Clear all

NCT04828486 2025-11-18

Futibatinib and Pembrolizumab for Treatment of Advanced or Metastatic FGF19 Positive BCLC Stage A, B, or C Liver Cancer

Phase 2 Completed

14 enrolled 13 charts

Gastrointestinal

Carcinoma, Hepatocellular